Xilio Therapeutics (XLO) Restructuring Costs (2024)

Xilio Therapeutics (XLO) reported Restructuring Costs of -$41000.0 for Q3 2024, down 236.67% sequentially from $30000.0 in Q2 2024.

Xilio Therapeutics (XLO) Restructuring Costs (2024) Analysis & Trends

Xilio Therapeutics (XLO) has 1 years of Restructuring Costs data on file, last reported at -$41000.0 in Q3 2024.

For the quarter ending Q3 2024, Restructuring Costs changed N/A year-over-year to -$41000.0; the trailing twelve-month figure through Dec 2024 stood at $937000.0 (changed N/A YoY), and the FY2024 full-year result was $937000.0, changed N/A from the prior year.
Restructuring Costs fell to -$41000.0 in Q3 2024, from $30000.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $948000.0 in Q1 2024 to a low of -$41000.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	65,839.48 Bn	65,839.20 Bn	-
2	Nanobiotix	1,914.07 Bn	1,914.01 Bn	-
3	Akari Therapeutics	1,009.43 Bn	1,009.43 Bn	-
4	BeOne Medicines	468.11 Bn	463.32 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.48 Bn	115.23 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.30 Bn	61.55 Bn	3.31 Bn
7	Belite Bio	62.77 Bn	62.77 Bn	-
8	Argenx Se	55.66 Bn	50.47 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.42 Bn	34.41 Bn	959.66 Mn
10	Xilio Therapeutics	145.98 Mn	-4.32 Mn	-

Download Data